Cancer Genetics Stock Company Profile

Description

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, India, and China. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biopharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company’s clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management. Its biopharma services offer companies with customized solutions for patient stratification and treatment selection through a suite of molecular- and biomarker-based testing services, customized assay development, and trial design consultation. The company’s discovery services provide the tools and testing methods for companies and researchers to identify new molecular-based biomarkers for disease. It serves hospitals, cancer centers, clinics, researchers, and academic institutions, as well as biopharma and biotech companies performing clinical trials. The company has a strategic alliance and partnership agreement with ApoCell to work on clinical trial projects that support the liquid biopsy and CTC profiling needs in various trials for targeted therapeutics and immuno-oncology. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.